Jubilant Pharmova’s arm inks Shareholders’ Agreement with Pierre Fabre SA

20 Mar 2025 Evaluate

Jubilant Pharmova’s step down subsidiary -- Jubilant Biosys Innovative Research Services (JBIRSPL) has executed Shareholders’ Agreement and other transition agreements with Pierre Fabre SA, and its affiliate entities (PF), and subscribed to 80% equity capital in JASMIN, with remaining 20% equity capital retained by PF. Simultaneously, the acquisition of PF’s R&D Centre (including R&D Site and R&D activities) at Saint Julien, France by JASMIN stands successfully closed. 

JASMIN is a company incorporated by PF in France, as a Societe par Actions Simplifiee (SAS). On closure of transaction, name of JASMIN has been changed to ‘Jubilant Biosys France’ which is now a subsidiary of JBIRSPL. 

JBIRSPL is a subsidiary of Jubilant Biosys, a wholly owned subsidiary of the company.

Jubilant Pharmova (formerly Jubilant Life Sciences) is a company engaged in pharmaceuticals, contract research and development services and proprietary novel drugs businesses.


Jubilant Pharmova Share Price

1076.50 7.30 (0.68%)
05-Dec-2025 15:04 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1805.15
Dr. Reddys Lab 1275.50
Cipla 1521.80
Zydus Lifesciences 931.80
Lupin 2100.85
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×